SVP, Business Development

VP, Finance & CAO

Director

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Institution	Shares	Value	Change
Vanguard	55,959,502	$20.3B	INCREASED
BlackRock	49,362,016	$17.9B	INCREASED
Capital Group	37,039,962	$13.4B	DECREASED
State Street	30,560,537	$11.1B	INCREASED
Invesco Ltd	16,320,446	$5.9B	INCREASED

Insider	Type	Shares	Value	Date
Rachna Khosla (SVP, Business Development)	EXERCISE	1,252	$204K	2026-08-11
Rachna Khosla (SVP, Business Development)	SELL	1,252	$521K	2026-08-11
Rachna Khosla (SVP, Business Development)	SELL	2,000	$825K	2026-08-11
Matthew C. Busch (VP, Finance & CAO)	AWARD	730		2026-08-07
Michael V Drake (Director)	AWARD	63		2026-08-07

Member	Type	Amount	Date
David J. Taylor (Republican)	SALE	$1,001 - $15,000	2026-08-26
David J. Taylor (Republican)	SALE	$1,001 - $15,000	2026-08-25
Sheldon Whitehouse (Democrat)	SALE	$1,001 - $15,000	2026-08-12

Amgen Inc (AMGN) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades